Skip to main content

Covalon Technologies Ltd(COV-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low1.770
Day High1.800
Open:1.790
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Covalon Technologies Ltd

Select a category then submit the form to load news
Business Wire
Covalon Reports on 2026 First Quarter Results and Recent Achievements and Highlights
Business Wire
Covalon Honoured to Partner with the Association for Vascular Access and Global Expert Dr. Nancy Moureau to Tackle Critical IV Therapy Complications
Business Wire
Covalon Announces Conference Call to Discuss First Quarter Fiscal 2026 Results
Newsfile
Upcoming Meeting Dates - January 19, 2026
Business Wire
Covalon Reports Highest Revenue Quarter of Fiscal Year 2025, Delivers Third Consecutive Year of Revenue Growth
Business Wire
Covalon Announces Conference Call to Discuss Fourth Quarter and Year End Fiscal 2025 Financial Results
Business Wire
Covalon Technologies Ltd. Announces Payment of First Ever Dividend, Marking a Milestone in Financial Strength
Business Wire
Covalon Declares First Ever Special Cash Dividend
Business Wire
Covalon to Participate in the Planet MicroCap Showcase: TORONTO on October 22, 2025
Business Wire
Empowering Nurses with Innovation: Covalon Showcases Patient Safety Solutions to Tackle Preventable Complications at ANCC National Magnet & Pathway Conference
Business Wire
Covalon Presents Evidence-Backed Innovations Making a Difference for Critically Ill Children at APHON
Business Wire
Covalon Announces Departure of Executive Chair and the Appointment of its Largest Shareholder as New Chair
Business Wire
Evidence-Driven Outcomes and Clinical Innovation Highlight Covalon’s Presence at the Association for Vascular Access 2025 Annual Meeting
Business Wire
Covalon Announces Publication of Impactful VALGuard® Line Guard Clinical Study Demonstrating Significant Reduction in Central Line-Associated Blood Stream Infections (CLABSIs)
Business Wire
Covalon Reports Strong Sequential Quarter on Quarter and Trailing Twelve Months Performance
Business Wire
Covalon Technologies Ltd. Achieves DTC Eligibility in the United States
Business Wire
Covalon Announces Conference Call to Discuss Third Quarter Fiscal 2025 Financial Results
AI-generated - The Globe and Mail
Covalon Technologies: Stocks Undervalued by Analyst Consensus on TSX-V (COV)
Business Wire
Covalon Reports Fifth Consecutive Quarter of Positive Earnings
Business Wire
Covalon Announces Exciting New Clinical Research Evaluating VALGuard® Vascular Access Line Guard
Business Wire
Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2025 Financial Results
Business Wire
Covalon Retains Financial and Strategic Advisor to Advise on Shareholder Value-Enhancing Opportunities
Business Wire
Covalon Announces Promotion of Kim Crooks to Chief Operating Officer and Appointment to Board of Directors
Business Wire
Covalon to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, May 6, 2025
Business Wire
Covalon to Present at the Planet MicroCap Showcase: VEGAS on April 23, 2025
Business Wire
Covalon Technologies Ltd. Poised for Strong Benefit From Positive US Tariff Outcome
Business Wire
Covalon Announces Voting Results from Fiscal 2024 Annual Meeting of Shareholders
Business Wire
Covalon To Hold Annual Meeting of Shareholders on Wednesday, March 19, 2025
Business Wire
Covalon Reports Fourth Consecutive Quarter of Year over Year Revenue Growth and Positive Earnings
Business Wire
Covalon Technologies Ltd. Named as a TSX Venture Exchange 2025 Top 50 Company
Business Wire
Covalon Announces Conference Call to Discuss First Quarter Fiscal 2025 Financial Results
Business Wire
Covalon Technologies Releases Statement on United States – Canada Trade Dispute

Profile

Covalon Technologies Ltd is engaged in the business of researching, developing, manufacturing, and marketing patent-protected medical products that improve patient outcomes in the areas of infection management, wound care, and surgical procedures. The company generates revenue through development contracts, licensing agreements, distribution contracts, and sales. Its products include IV dressings, surgical site protection products, vascular access protection products, and others, and its solutions include primary dressing cover, vascular access technologies, advanced wound care, sensitive skin solutions, custom medical coatings, and patient resource support.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.